公开(公告)号：US20090048258A1

公开(公告)日：2009-02-19

申请号：US11883357

申请日：2006-01-31

申请人： Masaki Ogino ,  Yoshihisa Nakada ,  Mitsuyuki Shimada ,  Kouhei Asano ,  Norikazu Tamura ,  Minori Masago

发明人： Masaki Ogino ,  Yoshihisa Nakada ,  Mitsuyuki Shimada ,  Kouhei Asano ,  Norikazu Tamura ,  Minori Masago

IPC分类号： A61K31/5375 ,  C07D277/46 ,  A61K31/426 ,  A61K31/167 ,  A61P3/10 ,  A61P3/04 ,  C07C233/11 ,  C07D265/30

CPC分类号： C07D277/46 ,  C07C235/78 ,  C07D207/34 ,  C07D213/75 ,  C07D215/38 ,  C07D231/14 ,  C07D231/38 ,  C07D239/42 ,  C07D295/12 ,  C07D333/36 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12

摘要： The present invention relate to a compound represented by the formula (I) or (II) wherein ring A is an optionally substituted ring (the ring should not be pyrrolidine, piperidine and piperazine), ring B is an optionally substituted aromatic ring, ring D is an optionally substituted ring, R1 and R2 are each independently a hydrogen atom or a substituent, R3 is a hydrogen atom or a C1-6 alkyl group, or R3 is bonded to ring A to form a non-aromatic ring, ring Aa is an optionally substituted aromatic hydrocarbon, Y is CH or N, Ra1 is an optionally substituted hydrocarbon group, and Ra2 and Ra3 are each independently a hydrogen atom or a substituent, or a salt thereof. The present invention provides a compound having a DGAT inhibitory activity, which is useful for the treatment or amelioration of diseases or pathologies caused by high expression or high activation of DGAT.

摘要翻译： 本发明涉及由式（I）或（II）表示的化合物，其中环A为任选取代的环（该环不应为吡咯烷，哌啶和哌嗪），环B为任选取代的芳环，环D 是任选取代的环，R 1和R 2各自独立地为氢原子或取代基，R 3为氢原子或C 1-6烷基，或R 3与环A键合形成非芳香环，环A a为 任选取代的芳烃，Y是CH或N，Ra1是任选取代的烃基，Ra2和Ra3各自独立地是氢原子或取代基，或其盐。 本发明提供具有DGAT抑制活性的化合物，其可用于治疗或改善由高表达或高活化DGAT引起的疾病或病理。